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Abstract
'The blanching activities of Betnovate and Celestoderm- V lotions
(betamethasone-17-valerate, 0,1%) and Diprosone lotion (beta-
methasone dipropionate, 0,55%) were determined by measuring
their ability to cause blanching of human skin after topical appli-
cation.
Betnovate and Celestoderm-V lotions produced almost identical
blanching profiles. Diprosone lotion displayed a statistically sig-
nificant superior blanching acitivityover both Betnovate and Ce-
lestoderm-V lotions over the whole timespan of the trial.
Introduction
IT has been well documented that the blanching assay first de-
scribed by McKenzie and Stoughton may be used as a reliable indi-
cator of the rate of release of a cortiocosteroid from topically applied
formulations (1). There is also a direct relationship between the
blanching activityof a topically applied corticosteroid and its clinical
efficacy (2).
This trial was performed to compare the blanching activities of two
lotions containing betamethasone-17-valerate (0,1%) and one lotion
containing betamethasone-17,21-dipropionate (0,05%).
Occlusion of the sites of application greatly enhances the blanching
effect due to increased penetration of thecorticosteroid intothe skin
(2), but the trial was performed in both the occluded and unoc-
cluded mode because in practice the .unoccluded mode is used
most often, especially in the case of lotions which are mainlyapplied
to the scalp and other hairy areas of the body.
The structure of the side chains at the 17 and 21 positions is prob-
ably responsible for the difference in activity of the two corticoste-
roids. McKenzie and Atkinson (3) reported differences in the poten-
cies of the 17-propionate and 17-valerate esters relativeto fluocino-
lone acetonide. Betamethasone-17-propionate was 190% more ef-
fective than fluocinolone acetonide and betamethasone-17-valerate
was 360% more effective than fluocinolone acetonide when evalu-
ated by the vasoconstriction assay. It can therefore be concluded
that the 17-valerate is almost twice as potent as the 17-propionate.
Ithasbeenshown(4)thattheeffectof betamethasone-17,21-dipro-
pionateis superiorto thatof betamethasone-17-valerate,with re-
spectto boththeblanchingandtherapeuticaction.This illustrates
theimportanceof the21-propionateinthe17,21-dipropionatewith
respect to the structureactivityrelationshipof betamethasone
esters(Figure1).
The presentstudythereforeservedthepurposeof comparingthe
blanchingactivitiesof thetwobetamethasone-17-valeratecontain-
ing lotions(BetnovateandCelestoderm-V)toeachotherandtothe
betamethasone-17,21-dipropionatecontaininglotion(Diprosone).
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Materials and methods
The threelotionswerepurchasedshortlybeforethetrialat a local
pharmacy.
TwelvehealthyCaucasianvolunteerswere selectedfroma panel
knownto showa responseto topicallyappliedcorticosteroids.No
. referencewasmadetosexorsteroidsensitivity.Thevolunteershad
not receivedtopical or systemiccorticosteroidsfor at least six
weekspriorto theinvestigation.
The lotions 'were applied to the flexor aspect of the forearm in four
different arrangements, each application pattern being chosen
randomly to avoid any bias during application and observation. Five
microliters of fhe lotion (equivalent to approximately 4mg) was ap-
plied to twelve 7mm square sites on each forearm of the volunteers
in a double blind fashion using a micro-pipette. The pipette was also
used to spreadthelotionsimmediatelyafterapplication. ~,
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In theoccludedmodethesiteswere coveredwitha non-porous
plasticcovering(BlendermSurgicaltape) and the non-occluded
siteswereprotectedbycardboardcoveringscut in sucha wayso
as toallowa freeflowof air.
The residualsteroidwasremovedfromall thesitessix hoursafter
applicationby gentlewashingwith soap and warm water.The
degreeof blanchingforeachsitewas recordedindependentlyby
threeexperiencedobserversat 7, 8, 9, 10,12, 14,16,18 and 28
hoursaft~rapplicationusinga Q-4scale:
0 = normalskin .
1 = slightvasoconstriction
2 = moreintensevasoconstriction
3 = generalevenvasoconstrictionwithdistinctblanching
4 = markedvasoconstrictionwithverydistinctblanching
The methodsusedto evaluatethe resultsweretheareaunderthe
curve(AUG),thenumberof sitesexhibitingblanching,thegraded
intensityof vasoconstrictionand a pairedcomparisonof adjacent
sites(5).Blanchingprofiles(Rgures2 and3) wereobtainedusing
thepercentageofthetotalpossiblescoreandthetimeinhoursafter
application.
R.sults and discussion
In the occluded mode the AUC for Diprosone was greater than that
of Calestoderm-V which was greater than that of Betnovate. In all the
methods of analysis there was no significant difference between
Betnovate and Celestoderm-V (except the graded response at 16
hours which was in favour of Celestoderm-V), and Diprosone was
significantly better in all the methods of analysis at most of the time
intervals - especially at the peak times, i.e. between 8 and 18
hours after application.
The AUC in the tlnoccluded mode was greatest,for Diprosone with
. Betnovate and Celestoderm-V giving very similar values. All the
other methods of analysis gave results of Diprosone being signifi-
.cantly better thiln Betnovate and Celestoderm-V. No significant dif-
ferences were exhibited between Betnovate and Celestoderm-V.
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Figure 2. Blanching profiles of lotions in the
occluded mode.
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Figure 3. Blanching profiles of lotions in the
unoccluded mode.
Themainconclusionsthatcan be drawnfromthistrialarethat:
(i) Diprosonelotionhasa statisticallysignificantsuperiorblanching
activityover Betnovatelotionand Celestoderm-Vlotion,even
thoughtheconcentrationofthecorticosteroidinDiprosonelotion
is halfofthatoftheothertwolotions.Itwouldbeexpectedthatif
theselotionswereformulatedcontainingthesame.concentration
of corticosteroid,the differences in the blanchingactivities
wouldbe evenmoremarked.
(ii) There are no statisticallysignificantdifferencesbetweenthe
blanching activitiesof Betnovatelotion and Celestoderm-V
lotion.Thisis notnecessarilyexpectedas it isa well-established
factthatthenatureof thebase affectsthereleaseof theactive
ingredient.Betnovatecream and Celestoderm-Vcreamshqw
similarblanchingactivities,whereasCelestoderm-Vointment
hasa superioractivitytothatof Betnovateointment(6);A similar
exampleof theinfluenceof thebase hasbeenobservedin the
cas.eof fluocinoloneacetonide(7).
It could be expected,however,thatdue to the good surface
coverage,skincontactandspreadibilityof lotions,thatthecorti-
costeroidwould be releasedequallywell fromdifferentlotion
~~ 0
Acknowledgements
One of us (E.M.) acknowledges the H. Bradlow Scholarship for post-
graduate studies.
References
1. McKenzie,AW., Stoughton,A.B. (1962)Arch.Derm.86: 608-610
2. McKenzie,AW., (1962)Arch. Derm.86: 611-614
3. McKenzie,AW., Atkinson,R.M. (1964)Arch. Derm.89: 741-746
4. Frederiksson,T., Gip, L., Hamlelt,A (1975)CurroTherap.Res. 18: 324-
331
5. Coleman,G.L.,Kanler,I., Haigh,J.M. (1978)Dermatologica156:224-230
6. Coleman,G.L. (1977)M.Sc. Thesis,RhodesUniversity,Grahamstown
7. Coleman,G.L., Magnus,AD., Haigh,J.M., Kanter,I. (1979)S. AIr.Med.J.
56: 447-448
. SA TydskritvirApteekV\lese-November1981
76
I
60
50
"10TPS
4-0
